Retro Biosciences
backed by Sam Altman, closed a funding round at a $1.8 billion valuation in May 2026, working on iPSC-derived, AAV and small-molecule therapies with the help of AI models.
- Country
- United States
$1.8B valuation
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Partial epigenetic reprogramming | regenerative-personalized | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.